LGND logo

LGND EBITDA

Annual EBITDA:

$60.41M+$13.17M(+27.89%)
December 31, 2024

Summary

  • As of today, LGND annual EBITDA is $60.41 million, with the most recent change of +$13.17 million (+27.89%) on December 31, 2024.
  • During the last 3 years, LGND annual EBITDA has fallen by -$47.18 million (-43.85%).
  • LGND annual EBITDA is now -66.52% below its all-time high of $180.42 million, reached on December 31, 2018.

Performance

LGND EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLGNDincome statement metrics

Quarterly EBITDA:

$62.85M+$44.19M(+236.90%)
September 30, 2025

Summary

  • As of today, LGND quarterly EBITDA is $62.85 million, with the most recent change of +$44.19 million (+236.90%) on September 30, 2025.
  • Over the past year, LGND quarterly EBITDA has increased by +$42.32 million (+206.24%).
  • LGND quarterly EBITDA is now -14.47% below its all-time high of $73.48 million, reached on June 30, 2018.

Performance

LGND Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLGNDincome statement metrics

TTM EBITDA:

$65.09M+$42.32M(+185.93%)
September 30, 2025

Summary

  • As of today, LGND TTM EBITDA is $65.09 million, with the most recent change of +$42.32 million (+185.93%) on September 30, 2025.
  • Over the past year, LGND TTM EBITDA has increased by +$9.51 million (+17.12%).
  • LGND TTM EBITDA is now -63.74% below its all-time high of $179.52 million, reached on December 31, 2018.

Performance

LGND TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherLGNDincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

LGND EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+27.9%+206.2%+17.1%
3Y3 Years-43.9%+130.0%-29.8%
5Y5 Years+58.9%+657.6%+57.2%

LGND EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-43.9%+27.9%at high+330.1%-29.8%+212.1%
5Y5-Year-43.9%+64.6%at high+330.1%-29.8%+212.1%
All-TimeAll-Time-66.5%+192.5%-14.5%+237.2%-63.7%+190.7%

LGND EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
$62.85M(+236.9%)
$65.09M(+185.9%)
Jun 2025
-
$18.65M(+168.3%)
$22.76M(+9.1%)
Mar 2025
-
-$27.32M(-350.5%)
$20.86M(-65.5%)
Dec 2024
$60.41M(+27.9%)
$10.90M(-46.9%)
$60.41M(+8.7%)
Sep 2024
-
$20.52M(+22.5%)
$55.57M(+23.8%)
Jun 2024
-
$16.75M(+36.9%)
$44.88M(+25.9%)
Mar 2024
-
$12.23M(+101.4%)
$35.66M(-24.4%)
Dec 2023
$47.23M(-16.0%)
$6.07M(-38.2%)
$47.20M(+51.7%)
Sep 2023
-
$9.83M(+30.6%)
$31.11M(-36.0%)
Jun 2023
-
$7.53M(-68.3%)
$48.60M(-24.5%)
Mar 2023
-
$23.77M(+337.2%)
$64.39M(+11.2%)
Dec 2022
$56.23M(-47.7%)
-$10.02M(-136.7%)
$57.89M(-37.5%)
Sep 2022
-
$27.33M(+17.2%)
$92.67M(+3.1%)
Jun 2022
-
$23.31M(+35.0%)
$89.86M(-0.7%)
Mar 2022
-
$17.27M(-30.3%)
$90.48M(-0.6%)
Dec 2021
$107.59M(+193.2%)
$24.76M(+1.0%)
$91.02M(+23.8%)
Sep 2021
-
$24.52M(+2.5%)
$73.55M(+28.3%)
Jun 2021
-
$23.93M(+34.4%)
$57.32M(+29.2%)
Mar 2021
-
$17.81M(+144.4%)
$44.37M(+20.4%)
Dec 2020
$36.70M(-3.5%)
$7.29M(-12.2%)
$36.84M(-11.0%)
Sep 2020
-
$8.29M(-24.4%)
$41.41M(+30.5%)
Jun 2020
-
$10.97M(+6.8%)
$31.73M(+56.1%)
Mar 2020
-
$10.28M(-13.3%)
$20.32M(-29.6%)
Dec 2019
$38.01M(-78.9%)
$11.86M(+959.8%)
$28.88M(-46.2%)
Sep 2019
-
-$1.38M(-217.0%)
$53.65M(-36.2%)
Jun 2019
-
-$435.00K(-102.3%)
$84.12M(-46.8%)
Mar 2019
-
$18.83M(-48.6%)
$158.03M(-12.0%)
Dec 2018
$180.42M(+123.9%)
$36.63M(+25.9%)
$179.52M(+2.4%)
Sep 2018
-
$29.09M(-60.4%)
$175.23M(+6.0%)
Jun 2018
-
$73.48M(+82.2%)
$165.34M(+53.7%)
Mar 2018
-
$40.32M(+24.7%)
$107.58M(+33.7%)
Dec 2017
$80.60M(+43.4%)
$32.34M(+68.5%)
$80.46M(+14.0%)
Sep 2017
-
$19.20M(+22.1%)
$70.61M(+17.6%)
Jun 2017
-
$15.72M(+19.1%)
$60.05M(+16.6%)
Mar 2017
-
$13.20M(-41.3%)
$51.49M(-8.4%)
Dec 2016
$56.21M(+81.5%)
$22.49M(+160.2%)
$56.21M(+23.1%)
Sep 2016
-
$8.64M(+20.8%)
$45.65M(-2.0%)
Jun 2016
-
$7.16M(-60.1%)
$46.59M(+4.3%)
Mar 2016
-
$17.91M(+50.1%)
$44.66M(+44.2%)
Dec 2015
$30.98M(+32.6%)
$11.94M(+24.5%)
$30.97M(+3.6%)
Sep 2015
-
$9.59M(+83.3%)
$29.89M(+21.1%)
Jun 2015
-
$5.23M(+23.9%)
$24.68M(+14.2%)
Mar 2015
-
$4.22M(-61.1%)
$21.62M(-7.5%)
Dec 2014
$23.37M(+25.3%)
$10.86M(+148.2%)
$23.37M(+18.1%)
Sep 2014
-
$4.38M(+102.3%)
$19.79M(+2.1%)
Jun 2014
-
$2.16M(-63.8%)
$19.38M(-2.7%)
Mar 2014
-
$5.97M(-18.0%)
$19.93M(+6.9%)
Dec 2013
$18.65M(+415.7%)
$7.28M(+83.7%)
$18.64M(+11.9%)
Sep 2013
-
$3.96M(+46.5%)
$16.66M(+38.9%)
Jun 2013
-
$2.71M(-42.3%)
$12.00M(+41.7%)
Mar 2013
-
$4.69M(-11.4%)
$8.47M(+134.2%)
Dec 2012
$3.62M(+36.5%)
$5.30M(+857.8%)
$3.62M(-18.9%)
Sep 2012
-
-$699.00K(+14.9%)
$4.46M(-1.2%)
Jun 2012
-
-$821.00K(-409.9%)
$4.51M(-7.3%)
Mar 2012
-
-$161.00K(-102.6%)
$4.87M(+37.8%)
Dec 2011
$2.65M(+129.0%)
$6.14M(+1051.9%)
$3.53M(+168.0%)
Sep 2011
-
-$645.00K(-38.1%)
-$5.19M(-27.1%)
Jun 2011
-
-$467.00K(+68.8%)
-$4.09M(+41.4%)
Mar 2011
-
-$1.50M(+42.2%)
-$6.97M(+16.3%)
Dec 2010
-$9.15M(+29.7%)
-$2.59M(-659.7%)
-$8.33M(-123.4%)
Sep 2010
-
$462.00K(+113.8%)
-$3.73M(+54.4%)
Jun 2010
-
-$3.35M(-17.4%)
-$8.17M(+4.9%)
Mar 2010
-
-$2.85M(-241.7%)
-$8.59M(+31.6%)
Dec 2009
-$13.01M
$2.02M(+150.7%)
-$12.57M(+22.5%)
DateAnnualQuarterlyTTM
Sep 2009
-
-$3.98M(-5.4%)
-$16.22M(+13.8%)
Jun 2009
-
-$3.77M(+44.7%)
-$18.82M(+10.0%)
Mar 2009
-
-$6.83M(-315.8%)
-$20.92M(+17.9%)
Dec 2008
-$25.99M(+50.3%)
-$1.64M(+75.0%)
-$25.49M(+20.4%)
Sep 2008
-
-$6.58M(-12.0%)
-$32.02M(+2.3%)
Jun 2008
-
-$5.87M(+48.4%)
-$32.77M(+20.7%)
Mar 2008
-
-$11.39M(-39.5%)
-$41.30M(+22.1%)
Dec 2007
-$52.32M(-146.5%)
-$8.17M(-11.4%)
-$53.04M(-14.8%)
Sep 2007
-
-$7.33M(+49.1%)
-$46.20M(+0.3%)
Jun 2007
-
-$14.41M(+37.7%)
-$46.36M(-19.0%)
Mar 2007
-
-$23.13M(-1636.4%)
-$38.97M(-151.2%)
Dec 2006
-$21.23M(-141.2%)
-$1.33M(+82.2%)
-$15.51M(-39.5%)
Sep 2006
-
-$7.49M(-6.6%)
-$11.12M(-362.5%)
Jun 2006
-
-$7.02M(-2273.4%)
-$2.40M(-184.9%)
Mar 2006
-
$323.00K(-89.4%)
$2.83M(+132.2%)
Dec 2005
-$8.80M(+61.8%)
$3.06M(+148.4%)
-$8.80M(-206.3%)
Sep 2005
-
$1.23M(+169.1%)
$8.28M(+276.4%)
Jun 2005
-
-$1.78M(+84.2%)
-$4.69M(+74.5%)
Mar 2005
-
-$11.31M(-156.2%)
-$18.38M(+17.7%)
Dec 2004
-$23.07M(-300.1%)
$20.14M(+271.6%)
-$22.35M(+21.6%)
Sep 2004
-
-$11.74M(+24.2%)
-$28.49M(-31.6%)
Jun 2004
-
-$15.48M(-1.3%)
-$21.64M(-81.8%)
Mar 2004
-
-$15.27M(-209.1%)
-$11.91M(-106.6%)
Dec 2003
-$5.77M(+65.9%)
$14.00M(+386.1%)
-$5.76M(+71.9%)
Sep 2003
-
-$4.89M(+14.8%)
-$20.50M(+5.1%)
Jun 2003
-
-$5.74M(+37.1%)
-$21.60M(+8.5%)
Mar 2003
-
-$9.13M(-1137.1%)
-$23.62M(-55.3%)
Dec 2002
-$16.92M(-2.1%)
-$738.00K(+87.7%)
-$15.21M(+3.0%)
Sep 2002
-
-$5.99M(+22.7%)
-$15.69M(-25.1%)
Jun 2002
-
-$7.76M(-972.8%)
-$12.54M(-18.1%)
Mar 2002
-
-$723.00K(+40.5%)
-$10.62M(+35.9%)
Dec 2001
-$16.56M(+57.4%)
-$1.22M(+57.3%)
-$16.56M(+29.1%)
Sep 2001
-
-$2.85M(+51.1%)
-$23.37M(+23.9%)
Jun 2001
-
-$5.83M(+12.6%)
-$30.70M(+16.4%)
Mar 2001
-
-$6.67M(+16.9%)
-$36.74M(+5.6%)
Dec 2000
-$38.91M(+21.2%)
-$8.03M(+21.1%)
-$38.91M(+4.7%)
Sep 2000
-
-$10.17M(+14.3%)
-$40.81M(+7.6%)
Jun 2000
-
-$11.87M(-34.2%)
-$44.18M(+6.4%)
Mar 2000
-
-$8.84M(+11.0%)
-$47.23M(+4.4%)
Dec 1999
-$49.38M(+24.4%)
-$9.93M(+26.6%)
-$49.39M(-53.2%)
Sep 1999
-
-$13.54M(+9.2%)
-$32.23M(+50.0%)
Jun 1999
-
-$14.91M(-35.6%)
-$64.49M(+0.4%)
Mar 1999
-
-$11.00M(-252.3%)
-$64.75M(+0.9%)
Dec 1998
-$65.31M(-144.6%)
$7.22M(+115.8%)
-$65.31M(+9.0%)
Sep 1998
-
-$45.80M(-201.8%)
-$71.73M(-112.7%)
Jun 1998
-
-$15.17M(-31.3%)
-$33.73M(-31.5%)
Mar 1998
-
-$11.56M(-1544.6%)
-$25.66M(-22.8%)
Dec 1997
-$26.70M(+7.9%)
$800.00K(+110.3%)
-$20.90M(+29.9%)
Sep 1997
-
-$7.80M(-9.9%)
-$29.80M(-22.1%)
Jun 1997
-
-$7.10M(-4.4%)
-$24.40M(+2.4%)
Mar 1997
-
-$6.80M(+16.0%)
-$25.00M(-7.8%)
Dec 1996
-$28.98M(-28.1%)
-$8.10M(-237.5%)
-$23.20M(-8.9%)
Sep 1996
-
-$2.40M(+68.8%)
-$21.30M(+17.1%)
Jun 1996
-
-$7.70M(-54.0%)
-$25.70M(-104.0%)
Mar 1996
-
-$5.00M(+19.4%)
-$12.60M(-14.5%)
Dec 1995
-$22.61M(-17.1%)
-$6.20M(+8.8%)
-$11.00M(-34.1%)
Sep 1995
-
-$6.80M(-225.9%)
-$8.20M(-41.4%)
Jun 1995
-
$5.40M(+258.8%)
-$5.80M(+65.1%)
Mar 1995
-
-$3.40M(0.0%)
-$16.60M(+9.8%)
Dec 1994
-$19.32M(-49.0%)
-$3.40M(+22.7%)
-$18.40M(-22.7%)
Sep 1994
-
-$4.40M(+18.5%)
-$15.00M(-41.5%)
Jun 1994
-
-$5.40M(-3.8%)
-$10.60M(-103.8%)
Mar 1994
-
-$5.20M
-$5.20M
Dec 1993
-$12.96M(-11.5%)
-
-
Dec 1992
-$11.63M
-
-

FAQ

  • What is Ligand Pharmaceuticals Incorporated annual EBITDA?
  • What is the all-time high annual EBITDA for Ligand Pharmaceuticals Incorporated?
  • What is Ligand Pharmaceuticals Incorporated annual EBITDA year-on-year change?
  • What is Ligand Pharmaceuticals Incorporated quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for Ligand Pharmaceuticals Incorporated?
  • What is Ligand Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
  • What is Ligand Pharmaceuticals Incorporated TTM EBITDA?
  • What is the all-time high TTM EBITDA for Ligand Pharmaceuticals Incorporated?
  • What is Ligand Pharmaceuticals Incorporated TTM EBITDA year-on-year change?

What is Ligand Pharmaceuticals Incorporated annual EBITDA?

The current annual EBITDA of LGND is $60.41M

What is the all-time high annual EBITDA for Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated all-time high annual EBITDA is $180.42M

What is Ligand Pharmaceuticals Incorporated annual EBITDA year-on-year change?

Over the past year, LGND annual EBITDA has changed by +$13.17M (+27.89%)

What is Ligand Pharmaceuticals Incorporated quarterly EBITDA?

The current quarterly EBITDA of LGND is $62.85M

What is the all-time high quarterly EBITDA for Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated all-time high quarterly EBITDA is $73.48M

What is Ligand Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?

Over the past year, LGND quarterly EBITDA has changed by +$42.32M (+206.24%)

What is Ligand Pharmaceuticals Incorporated TTM EBITDA?

The current TTM EBITDA of LGND is $65.09M

What is the all-time high TTM EBITDA for Ligand Pharmaceuticals Incorporated?

Ligand Pharmaceuticals Incorporated all-time high TTM EBITDA is $179.52M

What is Ligand Pharmaceuticals Incorporated TTM EBITDA year-on-year change?

Over the past year, LGND TTM EBITDA has changed by +$9.51M (+17.12%)
On this page